I am pleased to share entX’s Mid-Year Financial Report, highlighting strong progress across our commercialisation programs in space, defence, and healthcare.

Our proprietary technologies, including GenX and RHU power systems, continue to demonstrate their capacity to penetrate markets with traditionally high barriers to entry.

With two clear commercialisation priorities, radiation power systems and robust medical isotope supply chains, we remain focused on near-term cash generation while positioning entX to capture long-term global demand for sustainable energy and critical medical resources.

I invite you to review the full report for detailed financial results and key milestones achieved in the first half of FY25.

Bryn Jones Managing Director